Actively Recruiting
Dapagliflozin in Patients With Atrial Fibrillation (DAPA-AF)
Led by University of Oklahoma · Updated on 2026-04-01
28
Participants Needed
1
Research Sites
287 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The study will investigate the effect of Dapagliflozin on atrial fibrillation (AF) burden. AF burden will be defined as the percent of time spent in AF over a 2-week period, assessed by noninvasive continuous heart rhythm monitoring at baseline and at 3 months, quality of life (QOL) and validated echocardiographic indices of atrial myopathy. This knowledge will enable us to study the therapeutic potential of SGLT2i as a novel adjunct treatment for patients with DM and AF. Patients with paroxysmal AF (AF that terminates spontaneously or with intervention within seven days of onset) and DM and randomize them to Dapagliflozin or placebo. Continuous heart rhythm monitoring patch for AF burden will be used, measure of QOL with the help of AF Effect on Quality-of-life survey and perform an echocardiogram with measurement of left atrial volume index, left atrial strain and atrial tissue dopplers. All measurements will be performed at baseline and at study completion. The central hypothesis is that SGLT2i will lead to reduced AF burden that will translate into improvement in QOL, and the underlying mechanism is improvement in atrial myopathy.
CONDITIONS
Official Title
Dapagliflozin in Patients With Atrial Fibrillation (DAPA-AF)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with diabetes mellitus
- Paroxysmal atrial fibrillation (AF that terminates spontaneously or with intervention within seven days of onset)
You will not qualify if you...
- Type 1 diabetes mellitus
- Symptoms of low blood pressure or systolic blood pressure below 90 mmHg
- Severe kidney impairment with eGFR less than 30 mL/minute/1.73m2
- History of lower limb amputation
- Allergy or hypersensitivity to Dapagliflozin
- Currently taking any SGLT2 inhibitor medication
- Pregnancy
- Currently taking anti-arrhythmic drugs
- Undergoing catheter ablation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, United States, 73104
Actively Recruiting
Research Team
A
Aurora Vera
CONTACT
N
Natalia Wells-Serrano
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here